Select a community
All Communities
Home > Community Treatment Reports > Roxicodone (oxycodone) Treatment Report
What is Roxicodone?

Roxicodone® is a brand name for the drug oxyocodone is a powerful opioid medication used to treat moderate to severe pain.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Pain 12 2
General health 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 50%
Moderate
1 50%
Mild
0 0%
None
0 0%

Most commonly reported side effects

Nausea
2 100%
Constipation
1 50%
  • Mild
  • Moderate
  • Severe

Dosages

  15mg as needed 2 15mg as needed 5mg as needed 5 mg daily 15 mg daily 30 mg daily 45 mg daily 60 mg daily 90 mg daily 240 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2 2 Number of Patients: 2 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Roxicodone (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
1 100% Did not seem to work: 100%
Side effects too severe
1 100% Side effects too severe: 100%

See all 1 patient who’ve stopped taking Roxicodone

Currently Taking Roxicodone

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
3
1
2
4

Stopped Taking Roxicodone

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 50%
Usually
1 50%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
2 100%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 50%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 24, 2009.